How should a patient with chronic hepatitis B surface antigen (HBsAg) positivity be managed?

Management of HBsAg-Positive Patients

All HBsAg-positive patients with detectable HBV DNA should be considered candidates for antiviral therapy, with treatment decisions based primarily on HBV DNA levels, ALT elevation, fibrosis stage, and risk of disease progression 1.

Immediate Treatment Indications

Mandatory Treatment Groups

• Patients with cirrhosis: Treat if HBV DNA is detectable at ANY level, regardless of ALT 1
• Chronic hepatitis B with active disease: Treat if HBV DNA >2,000 IU/ml AND elevated ALT (>ULN) and/or significant fibrosis 1
• Advanced fibrosis (>F3 or LSM >8 kPa): Can treat if HBV DNA is detectable, regardless of level or ALT 1

Special Consideration Groups

• Persistently low HBV DNA (<2,000 IU/ml) with elevated ALT: Can treat, but first exclude other liver diseases 1
• Healthcare workers or high-risk transmission: Suppress HBV DNA to <2,000 IU/ml (or <200 IU/ml for exposure-prone procedures) 1
• Pregnant women: Target HBV DNA <200,000 IU/ml at birth to prevent mother-to-child transmission 1

Initial Assessment Algorithm

Laboratory Evaluation

1. HBV DNA quantification - Primary determinant of treatment need
2. ALT levels - Assess hepatic inflammation
3. HBeAg/anti-HBe status - Classify disease phase
4. Quantitative HBsAg (qHBsAg) - Emerging biomarker for monitoring 2
5. Reflex HDV testing - Rule out coinfection 2
6. Fibrosis assessment - Via liver stiffness measurement or biopsy

Risk Stratification

The 2025 EASL guidelines emphasize that early treatment prevents disease progression, HCC development, and improves survival 1. The evidence shows antiviral therapy leads to fibrosis reversal, clinical recompensation in advanced disease, and enhanced long-term outcomes 1.

Treatment Selection

First-Line Agents

Use potent nucleos(t)ide analogues (NAs):

• Tenofovir alafenamide (TAF) - Preferred for bone/renal concerns
• Tenofovir disoproxil fumarate (TDF) - Highly effective, monitor renal function
• Entecavir (ETV) - Effective but 0.9% resistance at 5 years in treatment-naïve patients 3

Critical caveat: TDF causes kidney tubular damage in up to 5% and 2.5% bone density loss; TAF avoids these issues. ETV resistance reaches 20% in treatment-experienced patients 3.

Monitoring Strategy

On-Treatment Monitoring

• HBV DNA: Every 3-6 months initially, then every 6-12 months once suppressed
• ALT: Every 3-6 months
• qHBsAg: Useful for predicting functional cure, especially with peginterferon-based regimens 4, 5
• HCC surveillance: Continue regardless of viral suppression in cirrhotic patients

Treatment Goals

1. Primary: HBV DNA suppression to undetectable levels
2. Optimal: HBsAg loss (functional cure) - though rarely achieved with current NAs 1
3. Prevent: HCC, cirrhosis progression, transmission

Special Populations

Immunosuppressed Patients

• HBsAg-positive patients: Require antiviral prophylaxis before immunosuppression to prevent reactivation 1
• Monitor HBV DNA and qHBsAg every 2 months during high-risk immunosuppression 6

Indeterminate/Grey Zone Patients

The 2025 guidelines recommend personalized assessment for HBeAg-positive or HBeAg-negative chronic infection patients 1. Recent evidence supports expanding treatment to these populations given the long-term HCC risk even with moderate HBV DNA levels (6-7 log10 IU/mL) 3.

Critical Pitfalls to Avoid

1. Non-adherence risk: 25.4% of patients on long-term NA therapy become non-adherent, with 1.2% experiencing severe hepatitis flares and 0.37% death or transplantation 3. Extensive counseling about adherence is mandatory before starting treatment.

2. Incomplete viral suppression: Patients with high viral loads may develop resistance, particularly with ETV. Switch to TDF or TAF if resistance develops 3.

3. Missing treatment opportunities: The expanding indications mean more patients qualify for treatment. Don't delay treatment in those with detectable HBV DNA and any degree of fibrosis 1.

4. Overlooking HCC surveillance: Continue surveillance even with viral suppression, especially in cirrhotic patients or those with family history of HCC.

Emerging Considerations

Quantitative HBsAg monitoring is increasingly important: baseline ALT/qHBsAg ratio ≥0.27 independently predicts HBsAg seroclearance 7. Over 40% of CHB patients have qHBsAg >1,000 IU/mL and are unlikely to achieve spontaneous clearance, making them candidates for novel antivirals 7.

The combination of HBsAg <1,000 IU/mL and HBV DNA <2,000 IU/mL accurately identifies true inactive carriers who may not require immediate treatment but need ongoing monitoring 5.